2022
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, O'Dwyer P, Benson A. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 41: 1359-1369. PMID: 36260828, PMCID: PMC9995105, DOI: 10.1200/jco.22.01013.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDacarbazineHumansNeuroendocrine TumorsPancreatic NeoplasmsProspective StudiesRetrospective StudiesTemozolomideTreatment OutcomeConceptsAdvanced pancreatic neuroendocrine tumorsProgression-free survivalPancreatic neuroendocrine tumorsMedian progression-free survivalPrimary end pointNeuroendocrine tumorsResponse rateObjective responseOverall survivalRandomized studyIntermediate-grade pancreatic neuroendocrine tumorsLonger progression-free survivalEnd pointMGMT deficiencyMedian overall survivalPrimary analysis populationKey eligibility criteriaPhase II trialSmall prospective studiesHigh response rateMethylguanine methyltransferaseCapecitabine/Eligible patientsSecondary endpointsII trialEverolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).
Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine Related Cancer 2022, 29: 335-344. PMID: 35324465, PMCID: PMC9257687, DOI: 10.1530/erc-21-0239.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDisease-Free SurvivalEverolimusHumansMTOR InhibitorsNeuroectodermal Tumors, PrimitiveVascular Endothelial Growth Factor AConceptsAdvanced pancreatic neuroendocrine tumorsProgression-free survivalPancreatic neuroendocrine tumorsVEGF pathway inhibitorsCombination armPrimary endpointMedian overall survival durationTreatment-related adverse eventsImproved progression-free survivalRandomized phase II studySuperior progression-free survivalPathway inhibitorOverall survival durationPhase II studyTreatment-related toxicityCombination of everolimusMTOR inhibitor everolimusHigh response rateAdverse eventsII studyInvestigator reviewCombination therapyStandard doseInhibitor everolimusNeuroendocrine tumors
2016
Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors
Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors. Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/mpa.0000000000000659.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineFluorouracilHumansNeuroendocrine TumorsOrganoplatinum CompoundsOxaliplatinProspective StudiesConceptsRadiographic response rateAdvanced neuroendocrine tumorsPrimary end pointProgression-free survivalNeuroendocrine tumorsPancreatic neuroendocrine tumorsNeuroendocrine carcinomaProspective phase II studyB studyEnd pointProlonged disease stabilityPhase II studyEffectiveness of bevacizumabDifferentiated neuroendocrine carcinomaPredictable toxicityRR-18Maintenance therapyDisease stabilityII studyRadiographic responsePatientsResponse rateNET subtypesBevacizumabMonths
2015
Carcinoid and Neuroendocrine Tumors: Building on Success
Kunz PL. Carcinoid and Neuroendocrine Tumors: Building on Success. Journal Of Clinical Oncology 2015, 33: 1855-1863. PMID: 25918282, DOI: 10.1200/jco.2014.60.2532.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoid TumorCell DifferentiationChemoembolization, TherapeuticChemotherapy, AdjuvantHumansNeoplasm StagingNeuroendocrine TumorsPatient SelectionPrecision MedicinePredictive Value of TestsRadiopharmaceuticalsTreatment Outcome
2010
Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer
Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-3952. PMID: 20564136, DOI: 10.1002/cncr.25246.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleHumansMaleMiddle AgedPrognosisRadiotherapy, AdjuvantRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedStomach NeoplasmsTreatment OutcomeConceptsIntensity-modulated radiotherapyCRT groupGastric cancerConformal radiotherapyIMRT patientsAcute gastrointestinal toxicityMedian radiation doseMedian serum creatinineGastroesophageal junction cancerOverall survival rateConcurrent chemotherapyKidney V20Liver V30Median liverRecent creatinineAdjuvant chemoradiotherapyAdjuvant therapyGastrointestinal toxicityIMRT groupLocoregional failurePostoperative chemoradiotherapyJunction cancerRenal functionSerum creatinineTreatment breaks